PEN:NYE-Penumbra Inc. (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 175.51

Change

+4.26 (+2.49)%

Market Cap

USD 2.10B

Volume

0.85M

Analyst Target

USD 252.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 198.11B
MDT Medtronic PLC

N/A

USD 113.61B
STE STERIS plc

N/A

USD 23.65B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.34B
SNN Smith & Nephew SNATS Inc

N/A

USD 13.45B
GMED Globus Medical

N/A

USD 9.84B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.18B
BIO Bio-Rad Laboratories Inc

N/A

USD 9.18B
GKOS Glaukos Corp

N/A

USD 7.36B
INSP Inspire Medical Systems Inc

N/A

USD 5.88B

ETFs Containing PEN

BWZ SPDR® Bloomberg Short Te.. 0.00 % 0.35 %

N/A

N/A
EPU iShares MSCI Peru ETF 0.00 % 0.59 %

N/A

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.23% 27% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.23% 27% F 6% D-
Trailing 12 Months  
Capital Gain -30.45% 34% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.45% 34% F 8% B-
Trailing 5 Years  
Capital Gain 8.26% 60% D- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.26% 60% D- 40% F
Average Annual (5 Year Horizon)  
Capital Gain 17.03% 81% B- 81% B-
Dividend Return 17.03% 81% B- 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.89% 28% F 19% F
Risk Adjusted Return 35.55% 72% C 55% F
Market Capitalization 2.10B 72% C 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 72.42 37% 9%
Price/Book Ratio 7.14 18% 12%
Price / Cash Flow Ratio 71.04 10% 3%
Price/Free Cash Flow Ratio 76.96 3% 2%
Management Effectiveness  
Return on Equity 1.28% 68% 34%
Return on Invested Capital 7.79% 83% 60%
Return on Assets 3.12% 69% 60%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.